Sinotherapeutics Inc.

688247

CNE100005PL9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-02 EDT			5-day change	1st Jan Change
8.9 ^CNY	-2.20%		-1.22%	-18.94%

04-29	Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-02	Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.	CI

Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange Composite Index

August 25, 2023 at 12:00 am

Sinotherapeutics Inc Added to Shanghai Stock Exchange Composite Index.

Latest news about Sinotherapeutics Inc.

Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.	04-01	CI
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Sinotherapeutics Inc. announces an Equity Buyback for CNY 70 million worth of its shares.	02-20	CI
Sinotherapeutics Inc. authorizes a Buyback Plan.	02-18	CI
Sinotherapeutics Gets Nod for Mesalazine Tablets; Shares Drop 7%	02-05	MT
Sinotherapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Sinotherapeutics' Unit Gets Registration Certificate for Sevelamer Carbonate Tablets	23-09-26	MT
Sinotherapeutics Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange A Share Index	23-08-25	CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange Composite Index	23-08-25	CI
Sinotherapeutics Gets US FDA Nod for Arthritis Drug	23-08-10	MT
Sinotherapeutics Signs Product Licensing Deal With US Drugmaker Lannett	23-08-07	MT
FDA Greenlights Sinotherapeutics' Mesalazine Enteric-Coated Tablets	23-05-17	MT
Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Sinotherapeutics Drug Selected in China's Centralized Drug Procurement	23-04-13	MT
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Sinotherapeutics’ Antifungal Drug Added to China’s Medical Insurance Catalog	23-01-19	MT
Sinotherapeutics Inc. has completed an IPO in the amount of CNY 424.8358 million.	22-08-22	CI

Sinotherapeutics Inc is China-based company mainly engaged in the research and development, commercial production and sales of pharmaceutical preparations. The Company's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The Company mainly operates in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SINOTHERAPEUTICS INC.	-18.94%	552M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+13.53%	41.95B
OTSUKA HOLDINGS CO., LTD.	+22.20%	22.53B
CIPLA LIMITED	+17.35%	14.11B
ZYDUS LIFESCIENCES LIMITED	+45.62%	12.5B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.44%	6.75B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.55%	5.6B
GEDEON RICHTER	+4.00%	4.95B